{
  "abstract": "Interleukin-1 (IL-1) blockers were first introduced into clinical practice approximately 15 years ago for the treatment of patients with glucocorticoid-dependent and colchicine-resistant (GD-CR) recurrent pericarditis. This marked a significant advancement that has radically changed the clinical landscape for this subgroup of patients.",
  "authors": [
    {
      "affiliations": [
        "First Cardiology Department, National and Kapodistrian University of Athens School of Medicine, Athens, Greece"
      ],
      "name": "George Lazaros"
    },
    {
      "affiliations": [
        "First Cardiology Department, National and Kapodistrian University of Athens School of Medicine, Athens, Greece"
      ],
      "name": "Costas Tsioufis"
    }
  ],
  "title": "Strategies for optimising tapering and withdrawal of interleukin-1 blockers in recurrent pericarditis",
  "uid": "d018d0af-81a0-5331-a459-139409242983"
}